Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 ...

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options ...

Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the July 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important ...

Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. pharmaceutical leaders, each backed by diversified product ...